Pharmalucence has been named as a “Rising Star” award winner for the Team Massachusetts Economic Impact Awards, awarded annually by MassEcon (Massachusetts Alliance for Economic Development). The awards celebrate companies that have made an outstanding contributions to the Massachusetts economy.
Pharmalucence receives FDA notification that Sulfur Colloid Injection (SCI) has been granted Orphan Drug designation status and seven years of market exclusivity for its use in lymph node localization in melanoma patients.
Pharmalucence has been selected as one of 19 finalists for the ninth annual MASSECON 2012 Team Massachusetts Economic Impact Awards. Finalists are selected on job growth, investment and facility expansion. The selected winners from each of the state’s five regions will be announced in October.
Glenn Alto, President and CEO, and Ed Connolly, COO, to present “Making it in Massachusetts: A Small Company’s Road to the CMO Market” at Interphex 2012.
For more details and to listen to an audio summary of their presentation visit:
Waltham, MA – The Massachusetts Life Sciences Center announced today that the Center’s Board of Directors has awarded $21.2 million in tax incentives to 28 life sciences companies. The recipient companies have committed to creating more than 940 new jobs in the Commonwealth this year.
The Life Sciences Tax Incentive Program, established in 2008 as part of the state’s ten- year, $1 billion Life Sciences Initiative, authorizes up to $25 million in tax incentives each year for companies engaged in life sciences research and development, commercialization, and manufacturing. The primary goal of the program is to incentivize life sciences companies to create new sustained jobs in Massachusetts.
The Life Sciences Act provides for ten different incentives, which address the significant capital expenditures associated with the life sciences R&D cycle and the high costs of translating research into commercially viable products. This is the third year that incentives have been provided under the program. Twenty-nine (29) companies have active tax incentive awards totaling $38.5 million awarded in 2009 and 2010. Those companies created a total of 1,588 jobs after receiving their tax incentives (1,106 of which were created by the companies under the Program).
While manufacturing operations and personnel remain in Bedford MA while our new facility project continues, all administrative staff has now relocated to 29 Dunham Road, Billerica, MA 01821. Our toll free number remains 1-800-221-7554, but some employee direct dial numbers have changed.
Pharmalucence Supplemental New Drug Application (sNDA) for the use of Sulfur Colloid Injection (SCI) in the localization of lymph nodes in melanoma patients has been accepted for review by FDA.